Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status-Reference-Cited by-同舟云学术

Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status

Published:2023-04-09 Issue:10 Volume:149 Page:7819-7829
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Kang Sora,Lee Myung-Won,Song Ik-Chan,Lee Hyo-Jin,Yun Hwan-Jung,Jo Deog-Yeon,Kim Jung Sun,Kwon Jung Hye,Kim Ji-Yeon,Lee Kyung-Ha,Ryu Hyewon

Funder

Ministry of Health & Welfare, Republic of Korea

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-04720-3.pdf

Reference16 articles.

1. Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont MJ, Alcaide J, Gómez A, López R, Manzano JL, Méndez Ureña M, Sastre J, Rivera F, Grávalos C, García T, Martín-Valadés JI, Falcó E, Navalón M, González Flores E, Ma García Tapiador A, Ma López Muñoz A, Barrajón E, Reboredo M, García Teijido P, Viudez A, Cárdenas N, Díaz-Rubio E (2018) First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study. Eur J Cancer 101:263–272. https://doi.org/10.1016/j.ejca.2018.06.024

2. Boige V, Francois E, Ben Abdelghani M, Phelip JM, Le Brun-Ly V, Mineur L, Galais MP, Villing A-L, Hautefeuille V, Miglianico L, De La Fouchardiere C, Genet D, Levasseur N, Levache C-B, Lachaux N, Gourgou S, Castan F, Bouché O (2021) Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: results of the randomized phase II PRODIGE 28-time UNICANCER study. J Clin Oncol 39:15–15. https://doi.org/10.1200/JCO.2021.39.3_suppl.15

3. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27:5727–5733. https://doi.org/10.1200/jco.2009.23.4344

4. Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, Gramont AD, Sobrero AF, Haller DG, Oki E, Shields AF, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Sougklakos I, Yoshino T, Meyerhardt JA, Andre T, Papamichail D, Taieb J (2022) Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials. J Clin Oncol 40:11–11. https://doi.org/10.1200/JCO.2022.40.4_suppl.011

5. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16:1355–1369. https://doi.org/10.1016/s1470-2045(15)00042-x

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04